L-Arginine Supplementation and Metabolism in Asthma

L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit...

Full description

Saved in:
Bibliographic Details
Main Authors: Angela Linderholm (Author), Nicholas J. Kenyon (Author), Erin O'Roark (Author), Vivian W. Kwan (Author), Jennifer M. Bratt (Author), Michael Last (Author)
Format: Book
Published: MDPI AG, 2011-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0284270ca25e47d390c12eba9c57c4b2
042 |a dc 
100 1 0 |a Angela Linderholm  |e author 
700 1 0 |a Nicholas J. Kenyon  |e author 
700 1 0 |a Erin O'Roark  |e author 
700 1 0 |a Vivian W. Kwan  |e author 
700 1 0 |a Jennifer M. Bratt  |e author 
700 1 0 |a Michael Last  |e author 
245 0 0 |a L-Arginine Supplementation and Metabolism in Asthma 
260 |b MDPI AG,   |c 2011-01-01T00:00:00Z. 
500 |a 10.3390/ph4010187 
500 |a 1424-8247 
520 |a L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebo-controlled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10−3 vs. 1.1 ± 0.2 × 10−3 µmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 µmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10−1 vs. 2.6 ± 0.6 × 10−1 µmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study. 
546 |a EN 
690 |a asthma 
690 |a L-arginine 
690 |a nitric oxide 
690 |a arginase 
690 |a ADMA 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 4, Iss 1, Pp 187-201 (2011) 
787 0 |n http://www.mdpi.com/1424-8247/4/1/187/ 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/0284270ca25e47d390c12eba9c57c4b2  |z Connect to this object online.